HF 2906 Minnesota House · 2025-2026 Regular Session

Psilocybin therapeutic use program established; protections for registered patients, designated cultivators, registered facilitators, and health care practitioners established; rulemaking authorized; civil actions authorized; fees established; advisory committee established; criminal penalties provided; and money appropriated.

HF 2906 establishes Minnesota's first legal framework for the therapeutic use of psilocybin (magic mushrooms) by adults 21+ with qualifying medical conditions. It creates a regulated program where patients must be certified by a licensed healthcare provider, enroll with the state health commissioner, and use psilocybin under supervision from registered facilitators during designated sessions. The bill sets rules for qualifying conditions, limits on cultivators, safety screenings, and requires the commissioner to develop detailed operational rules with input from an advisory committee. It also creates legal protections for participants, establishes fees for registration, and appropriates state funds to support the program. This is strictly a medical program with no recreational use permitted.

Bill status in committee 1 of 4 stages cleared

Introduction

Mar 2025

Committee Review

Floor Vote

Governor

Introduced Mar 27, 2025 Last action Apr 22, 2026

Maddy AI version diff · 1 comparison

What changed between versions

Introduction → 1st Engrossment · 7 edits · Mar 16, 2026

MODERATE

The bill was updated from its initial introduction to its first engrossment, reflecting significant substantive changes to the psilocybin therapeutic use program. Key modifications include shifting medical oversight from general 'health care practitioners' to specific 'physicians,' introducing a new role for 'registered facilitators' to supervise sessions, and establishing a formal 'treatment facility' requirement for administration sessions. The bill also expands the list of qualifying medical conditions, adds a research institution for data collection, and extends the rulemaking deadline from 2026 to 2027.

Scope change

The bill's scope expanded to require a registered facilitator and a treatment facility for all psilocybin administration sessions, moving away from a model where patients could self-administer at home without supervision. It also introduced a new requirement for an interagency agreement between the Department of Health and the Office of Cannabis Management.

ELIGIBILITY

Medical certification for program enrollment is now restricted to 'physicians' rather than any 'health care practitioner' (e.g., nurses or physician assistants).

REQUIREMENT

A new 'registered facilitator' role was created to supervise administration sessions, conduct preparation sessions, and lead integration sessions with patients.

Administration sessions must now occur at a licensed 'treatment facility' rather than solely at a patient's private residence.

A new 'Program research institution' is established to advise on data collection, training, and ethical oversight, replacing the previous reliance solely on the advisory committee.

DEFINITION

The definition of 'Qualifying medical condition' was expanded to explicitly include posttraumatic stress disorder, depression, substance use disorders, anxiety, and chronic pain.

TIMELINE

The deadline for publishing proposed rules in the State Register was extended from January 1, 2026, to January 1, 2027.

ENFORCEMENT

New contraindicated medications (lithium, MAOIs, tramadol, amphetamine stimulants) were added to the screening requirements.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Mar 16, 2026

Lower · Passed

Committee report, to adopt as amended and re-refer to Commerce Finance and Policy

lower

Mar 27, 2025

Introduced

Introduction and first reading, referred to Health Finance and Policy

lower

1 primary · 9 co-sponsors